NO20024971L - Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger - Google Patents

Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger

Info

Publication number: NO20024971L
Authority: NO; Norway
Prior art keywords: formulation; active substance; particles; inhalation device; inhalers
Prior art date: 2000-04-17

Application number

NO20024971A

Other languages

English (en)

Norwegian (no)

Other versions

NO20024971D0 (no

Inventor

John Nicholas Staniforth

David Alexander Vodden Morton

Rajbir Gill

Gaetano Brambilla

Rossella Musa

Lorenzo Ferrarini

Original Assignee

Vectura Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-17

Filing date

2002-10-16

Publication date

2002-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024971(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-04-17 Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en

2002-10-16 Application filed by Vectura Ltd filed Critical Vectura Ltd

2002-10-16 Publication of NO20024971D0 publication Critical patent/NO20024971D0/no

2002-12-17 Publication of NO20024971L publication Critical patent/NO20024971L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Dispersion Chemistry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20024971A 2000-04-17 2002-10-16 Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger NO20024971L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0009469.8A GB0009469D0 (en)	2000-04-17	2000-04-17	Improvements in or relating to formalities for use in inhaler devices
EP00113608		2000-06-27
PCT/GB2001/001732 WO2001078694A2 (fr)	2000-04-17	2001-04-17	Perfectionnements apportes ou relatifs a des formulations destinees a etre utilisees dans des dispositifs d'inhalation

Publications (2)

Publication Number	Publication Date
NO20024971D0 NO20024971D0 (no)	2002-10-16
NO20024971L true NO20024971L (no)	2002-12-17

Family

ID=26071084

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO20024973A NO342999B1 (no)	2000-04-17	2002-10-16	Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav
NO20024980A NO332025B1 (no)	2000-04-17	2002-10-16	Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter
NO20024971A NO20024971L (no)	2000-04-17	2002-10-16	Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger
NO20110885A NO336687B1 (no)	2000-04-17	2011-06-20	Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO20024973A NO342999B1 (no)	2000-04-17	2002-10-16	Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav
NO20024980A NO332025B1 (no)	2000-04-17	2002-10-16	Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20110885A NO336687B1 (no)	2000-04-17	2011-06-20	Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter

Country Status (32)

Country	Link
US (4)	US6884794B2 (fr)
EP (6)	EP2272508B1 (fr)
JP (2)	JP2003530425A (fr)
KR (1)	KR20030069047A (fr)
CN (1)	CN1424909A (fr)
AT (5)	ATE377416T1 (fr)
AU (3)	AU2001258343A1 (fr)
BR (3)	BR0110139A (fr)
CA (3)	CA2406119C (fr)
CY (1)	CY1107315T1 (fr)
CZ (1)	CZ301904B6 (fr)
DE (3)	DE60125344T2 (fr)
DK (3)	DK1719505T3 (fr)
DZ (1)	DZ3315A1 (fr)
EE (1)	EE05257B1 (fr)
ES (3)	ES2272473T3 (fr)
GB (2)	GB2363987A (fr)
HU (4)	HU230464B1 (fr)
IL (1)	IL152306A0 (fr)
MA (1)	MA26892A1 (fr)
MX (3)	MXPA02010213A (fr)
MY (1)	MY129384A (fr)
NO (4)	NO342999B1 (fr)
NZ (1)	NZ521887A (fr)
PE (1)	PE20011227A1 (fr)
PL (3)	PL204213B1 (fr)
PT (3)	PT1276472E (fr)
SA (1)	SA01220062B1 (fr)
SI (2)	SI1274406T1 (fr)
SK (1)	SK284248B6 (fr)
TN (1)	TNSN01060A1 (fr)
WO (3)	WO2001078693A2 (fr)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9501841D0 (en) *	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) *	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) *	1997-02-21	1997-04-09	Bradford Particle Design Ltd	Method and apparatus for the formation of particles
US20070212422A1 (en) *	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
US20060171899A1 (en) *	1998-12-10	2006-08-03	Akwete Adjei	Water-stabilized aerosol formulation system and method of making
IT1309592B1 (it) *	1999-03-05	2002-01-24	Chiesi Farma Spa	Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
DE69936268T2 (de) *	1999-03-05	2008-02-14	Chiesi Farmaceutici S.P.A.	Verbesserte pulverförmige pharmazeutische Zusammensetzungen zur Verwendung in Trockenpulverinhalatoren
GB0009468D0 (en) *	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) *	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en)	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formalities for use in inhaler devices
GB0012260D0 (en)	2000-05-19	2000-07-12	Astrazeneca Ab	Novel composition
GB0012261D0 (en)	2000-05-19	2000-07-12	Astrazeneca Ab	Novel process
DK1913939T3 (en)	2000-06-27	2017-09-18	Vectura Ltd	Formulations for use in inhalers
GB0027357D0 (en) *	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
JP4380988B2 (ja) †	2000-11-30	2009-12-09	ヴェクトゥラリミテッド	医薬組成物に用いられる粒子の製造方法
EP2168571B1 (fr)	2000-11-30	2018-08-22	Vectura Limited	Compositions pharmaceutiques pour inhalation
PT1337240E (pt)	2000-11-30	2011-11-02	Vectura Ltd	Método de fabrico de partículas para utilização numa composição farmacêutica
WO2002056948A1 (fr)	2001-01-17	2002-07-25	Vectura Limited	Dispositif d'inhalation
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
JP2005507881A (ja)	2001-09-17	2005-03-24	グラクソ　グループ　リミテッド	乾燥粉末医薬製剤
US7931533B2 (en)	2001-09-28	2011-04-26	Igt	Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv)	2002-02-01	2002-02-01	Astrazeneca Ab	Novel composition
AU2002330390A1 (en) *	2002-03-20	2003-09-29	Hosokawa Micron Corporation	Method of manufacturing chemical-containing composite particles
FI116657B (fi) *	2002-03-28	2006-01-31	Focus Inhalation Oy	Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) *	2002-04-09	2003-12-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) *	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
GB0216562D0 (en)	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
MXPA05001903A (es) *	2002-08-21	2005-04-28	Norton Healthcare Ltd	Composicion para inhalacion.
WO2004028545A1 (fr) *	2002-09-25	2004-04-08	Astrazeneca Ab	Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (fr) *	2003-02-27	2004-09-01	CHIESI FARMACEUTICI S.p.A.	Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
US20060147389A1 (en) *	2004-04-14	2006-07-06	Vectura Ltd.	Devices and pharmaceutical compositions for enhancing dosing efficiency
CA2522158C (fr) *	2003-04-14	2018-03-20	Vectura Ltd.	Dispositifs et compositions pharmaceutiques destines a ameliorer l'efficacite du dosage
US7094545B2 (en) *	2003-04-30	2006-08-22	Ferring Bv	Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP1643973A1 (fr) *	2003-07-11	2006-04-12	Glaxo Group Limited	Preparations pharmaceutiques contenant du stearate de magnesium
EP1646370A1 (fr) *	2003-07-11	2006-04-19	Glaxo Group Limited	Formulations pharmaceutiques
ES2243840T3 (es) *	2003-07-25	2005-12-01	Ferring B.V.	Composicion farmaceutica de desmopresina como forma farmaceutica solida de dosificacion y metodo para la fabricacion de la misma.
CN1826099B (zh) *	2003-07-25	2010-06-09	凡林有限公司	固体剂型药物组合物及其制造方法
WO2005025535A2 (fr) *	2003-09-15	2005-03-24	Vectura Limited	Procedes de preparation de compositions pharmaceutiques
GB0321607D0 (en) *	2003-09-15	2003-10-15	Vectura Ltd	Manufacture of pharmaceutical compositions
GB0327723D0 (en)	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
GB0324918D0 (en) *	2003-10-24	2003-11-26	Glaxo Group Ltd	Composition
GB0326632D0 (en) *	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
SE0303570L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Fukt-känslig medicinsk produkt
CA2547782A1 (fr) *	2003-12-03	2005-06-16	Microdrug Ag	Produit medical contenant du tiotropium
SE0303269L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Medicinsk produkt
SE0303569L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	DPI för avlämning av fuktkänsliga medikament
SE0303571D0 (sv) *	2003-12-03	2003-12-22	Microdrug Ag	Medical product for moisture-sensitive medicaments
SE0303270L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Metod för administration av tiotropium
US7018653B2 (en) *	2003-12-29	2006-03-28	Ferring B.V.	Method for preparing solid dosage form of desmopressin
JO3102B1 (ar)	2004-03-17	2017-09-20	Chiesi Framaceutici S P A	صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
KR101725225B1 (ko)	2004-04-23	2017-04-12	사이덱스 파마슈티칼스, 인크.	술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
GB0409703D0 (en)	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
GB0426301D0 (en) *	2004-11-30	2004-12-29	Vectura Ltd	Pharmaceutical formulations
MX2007009656A (es)	2005-02-10	2007-11-07	Glaxo Group Ltd	Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
JPWO2006095788A1 (ja) *	2005-03-09	2008-08-14	小野薬品工業株式会社	粒子およびその粒子を含有する製剤
MX2007012084A (es) *	2005-03-30	2007-11-21	Schering Corp	Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
TWI274641B (en) *	2005-08-30	2007-03-01	Rexon Ind Corp Ltd	Cutting machine
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en)	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
GB0613161D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
EP1944018A1 (fr) *	2007-01-10	2008-07-16	CHIESI FARMACEUTICI S.p.A.	Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
ES2691033T3 (es)	2007-02-11	2018-11-23	Map Pharmaceuticals Inc.	Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
KR20100044225A (ko)	2007-07-21	2010-04-29	알바니 몰레큘라 리써치, 인크.	5-피리디논 치환된 인다졸
CN103351390A (zh)	2007-11-21	2013-10-16	解码遗传Ehf公司	用于治疗肺部和心血管病症的联芳基pde4 抑制剂
JP5240205B2 (ja)	2008-01-11	2013-07-17	アステラス製薬株式会社	精巣の疼痛又は不快感行動及び頻尿併発モデル動物
JP5501251B2 (ja)	2008-01-11	2014-05-21	アルバニーモレキュラーリサーチ，インコーポレイテッド	Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
EP2080508A1 (fr)	2008-01-15	2009-07-22	CHIESI FARMACEUTICI S.p.A.	Formulation de poudre sèche comprenant un médicament anticholinérgique
WO2010059836A1 (fr)	2008-11-20	2010-05-27	Decode Genetics Ehf	Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
EP2191821A1 (fr) *	2008-11-26	2010-06-02	CHIESI FARMACEUTICI S.p.A.	Microparticles contenant une sel de 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone avec adhesion ameliorée pour l'inhalation de poudre sèche
US8673931B2 (en)	2009-01-26	2014-03-18	Abraham Fisher	Bicyclic heterocyclic spiro compounds
US9925282B2 (en)	2009-01-29	2018-03-27	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (fr) *	2009-02-25	2010-09-02	Chiesi Farmaceutici S.P.A.	Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
JP5809985B2 (ja)	2009-02-26	2015-11-11	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
EP2421514A2 (fr) *	2009-04-24	2012-02-29	Schering Corporation	Préparations d'agglomérat utiles dans des inhalateurs à poudre sèche
WO2011015289A1 (fr)	2009-08-04	2011-02-10	Chiesi Farmaceutici S.P.A.	Hémi-fumarate de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1h)-quinolinone
GB0918249D0 (en)	2009-10-19	2009-12-02	Respivert Ltd	Compounds
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
EP2360147A1 (fr)	2010-02-22	2011-08-24	CHIESI FARMACEUTICI S.p.A.	Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
CN102858326A (zh)	2010-04-01	2013-01-02	奇斯药制品公司	用于制备可吸入干粉所用的载体颗粒的方法
CN102858320B (zh) *	2010-04-21	2014-10-29	奇斯药制品公司	用于提供具有减少的静电荷的颗粒的方法
US9011852B2 (en)	2010-04-30	2015-04-21	Alexion Pharmaceuticals, Inc.	Anti-C5a antibodies
EP2575786B1 (fr)	2010-06-03	2017-11-15	Sima Patent ve Lisanslama Hizmetleri Ltd.Sti.	Procédé pour formulations pulvérulentes sèches
WO2011160920A1 (fr) *	2010-06-22	2011-12-29	Chiesi Farmaceutici S.P.A.	Formulation de poudre sèche comprenant un médicament antimuscarinique
UA112296C2 (uk) *	2010-08-03	2016-08-25	К'Єзі Фармачеутічі С.П.А.	Сухий порошковий препарат, який містить інгібітор фосфодіестерази
WO2012028745A1 (fr) *	2010-09-03	2012-03-08	Pharmaterials Limited	Composition pharmaceutique adaptée pour une utilisation dans un inhalateur de poudre sèche
CN107096014B (zh)	2010-09-29	2022-07-15	普马特里克斯营业公司	吸入用单价金属阳离子干粉剂
CA2813096C (fr)	2010-09-30	2019-10-29	Chiesi Farmaceutici S.P.A.	Utilisation de stearate de magnesium dans des preparations en poudre seche destinees a etre inhalees
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
US9808030B2 (en)	2011-02-11	2017-11-07	Grain Processing Corporation	Salt composition
TR201205852A2 (tr) *	2011-06-02	2012-12-21	Bi̇lgi̇ç Mahmut	Geliştirilmiş yeni kuru toz formülasyonu.
TR201105367A2 (tr) *	2011-06-02	2012-12-21	Bi̇lgi̇ç Mahmut	Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
WO2013109211A1 (fr) *	2012-01-16	2013-07-25	Mahmut Bilgic	Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
WO2013109208A1 (fr) *	2012-01-16	2013-07-25	Mahmut Bilgic	Formulations comprenant du formotérol utilisé comme agent actif
WO2013109214A1 (fr) *	2012-01-16	2013-07-25	Mahmut Bilgic	Procédé de préparation de formulations en poudre sèche
HUE060421T2 (hu) *	2012-01-25	2023-02-28	Chiesi Farm Spa	Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
US20150010527A1 (en)	2012-02-01	2015-01-08	Protalix Ltd.	Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US20150136130A1 (en)	2012-02-29	2015-05-21	Pulmatrix, Inc.	Inhalable dry powders
DK2834244T3 (en)	2012-03-13	2016-11-28	Respivert Ltd	CYSTALLINE PI3-KINASE INHIBITORS
US9763965B2 (en)	2012-04-13	2017-09-19	Glaxosmithkline Intellectual Property Development Limited	Aggregate particles
WO2014007771A2 (fr)	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
WO2014007772A2 (fr) *	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Compositions d'inhalation contenant du glucose anhydre
CA3111941A1 (fr)	2012-10-25	2014-05-01	The General Hospital Corporation	Polytherapies pour le traitement de la maladie d'alzheimer et des troubles associes
US11052202B2 (en)	2012-11-07	2021-07-06	Chiesi Farmaceutici S.P.A.	Drug delivery device for the treatment of patients with respiratory diseases
US9757395B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
KR20200105983A (ko)	2013-01-28	2020-09-09	인코젠 쎄라퓨틱스 프라이빗 리미티드	로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
JP6505079B2 (ja)	2013-03-29	2019-04-24	アレクシオンファーマシューティカルズ，インコーポレイテッド	補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
CN105473133A (zh)	2013-04-30	2016-04-06	欧缇托匹克公司	干粉制剂及使用方法
US10525005B2 (en)	2013-05-23	2020-01-07	The General Hospital Corporation	Cromolyn compositions and methods thereof
TR201802969T4 (tr) *	2013-07-01	2018-03-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Yeni inhalasyon formülasyonları.
ES2699986T3 (es) *	2013-07-11	2019-02-13	Chiesi Farm Spa	Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
US20160235667A1 (en) *	2013-10-02	2016-08-18	Vectura Limited	Method and apparatus for making compositions for pulmonary administration
US9427376B2 (en)	2013-10-10	2016-08-30	Chiesi Farmaceutici S.P.A.	Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN106102737B (zh)	2013-10-22	2019-06-14	综合医院公司	色甘酸衍生物以及成像和治疗的相关方法
NZ711451A (en)	2014-03-07	2016-05-27	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en)	2014-06-09	2017-01-31	Chiesi Farmaceutici S.P.A.	Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
EP2957552B1 (fr)	2014-06-16	2020-01-22	Arven Ilac Sanayi Ve Ticaret A.S.	Formulations de vilanterol
TR201407010A2 (tr)	2014-06-16	2015-12-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Vilanterol formülasyonları.
TR201818680T4 (tr) *	2014-07-09	2019-01-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
US20170304459A1 (en)	2014-10-10	2017-10-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhalation delivery of conjugated oligonucleotide
CA2965759C (fr)	2014-10-31	2023-12-12	Glaxosmithkline Intellectual Property Development Limited	Polypeptides en poudre presentant moins d'impuretes de disulfide comprenant des materiaux cationiques divalents
RU2693201C1 (ru) *	2015-06-23	2019-07-01	Шлюмберже Текнолоджи Б.В.	Распознание расклинивающего агента с помощью мобильного устройства
US11224594B2 (en) *	2015-09-16	2022-01-18	Philip Morris Products S.A.	Nicotine formulations and methods of making and using the same
ME03778B (fr) *	2015-11-16	2021-04-20	Chiesi Farm Spa	Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
HUE056402T2 (hu)	2015-11-16	2022-02-28	Chiesi Farm Spa	Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
UA123586C2 (uk)	2015-12-24	2021-04-28	Філіп Морріс Продактс С.А.	Капсула із частинками нікотину
WO2018045217A1 (fr)	2016-08-31	2018-03-08	The General Hospital Corporation	Macrophages/microglies dans la neuro-inflammation associée aux maladies neurodégénératives
CA3060020A1 (fr)	2017-05-11	2018-11-15	Chiesi Farmaceutici S.P.A.	Procede de preparation d'une formulation de poudre seche comprenant un anticholinergique, un corticosteroide et un beta-adrenergique
WO2018206619A1 (fr)	2017-05-11	2018-11-15	Chiesi Farmaceutici S.P.A.	Procédé de préparation d'une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
US10583085B2 (en)	2017-05-17	2020-03-10	Chiesi Farmaceutici S.P.A.	Carrier particles for dry powder formulations for inhalation
AU2018300237A1 (en)	2017-07-14	2020-01-16	Cytomx Therapeutics, Inc.	Anti-CD166 antibodies and uses thereof
CN111107788B (zh) *	2017-07-26	2023-12-19	深圳帧观德芯科技有限公司	具有空间扩展性x射线源的x射线成像系统
EP3658184B1 (fr)	2017-07-27	2023-09-06	Alexion Pharmaceuticals, Inc.	Formules d'anticorps anti-c5 à haute concentration
WO2019060604A1 (fr)	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	Médicament inhalable
KR102507987B1 (ko) *	2017-09-22	2023-03-21	벡추라 인코포레이티드	스테아르산마그네슘을 갖는 건조 분말 조성물
WO2019060797A1 (fr)	2017-09-22	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	Procédé de fabrication de poudres à inhaler
US10786456B2 (en)	2017-09-22	2020-09-29	Otitopic Inc.	Inhaled aspirin and magnesium to treat inflammation
WO2019067708A1 (fr) *	2017-09-27	2019-04-04	Teva Branded Pharmaceutical Products R&D, Inc.	Procédé pour diminuer la taille de particules
EP3700928A1 (fr)	2017-10-26	2020-09-02	Alexion Pharmaceuticals, Inc.	Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) et du syndrome hémolytique et urémique atypique (ahus)
EP3817739A4 (fr) *	2018-07-02	2022-04-13	The General Hospital Corporation	Formulations en poudre de cromoglycate de sodium et d'?-lactose
US11813360B2 (en)	2018-07-27	2023-11-14	Chiesi Farmaceutici S.P.A.	Carrier particles for dry powder formulations for inhalation
US10966943B2 (en)	2018-09-06	2021-04-06	Innopharmascreen Inc.	Methods and compositions for treatment of asthma or parkinson's disease
ES2969709T3 (es)	2018-10-30	2024-05-22	Chiesi Farm Spa	Aparato para administrar fármacos a pacientes ventilados mecánicamente
WO2020123691A2 (fr)	2018-12-12	2020-06-18	Kite Pharma, Inc	Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et méthodes d'utilisation
AU2020265576A1 (en)	2019-04-29	2021-11-25	Insmed Incorporated	Dry powder compositions of treprostinil prodrugs and methods of use thereof
MX2022003427A (es)	2019-09-24	2022-04-18	Chiesi Farm Spa	Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.
AU2021259628A1 (en)	2020-04-24	2023-01-05	Millennium Pharmaceuticals, Inc.	Anti-CD19 antibodies and uses thereof
WO2021237109A1 (fr)	2020-05-22	2021-11-25	Trailhead Biosystems Inc.	Polythérapie pour le traitement d'infections virales
CN112451509B (zh) *	2020-12-19	2023-03-07	沈阳药科大学	一种川丁特罗吸入粉雾剂及其制备方法
WO2022215054A1 (fr)	2021-04-09	2022-10-13	Takeda Pharmaceutical Company Limited	Anticorps ciblant le facteur d du complément et leurs utilisations
TW202305003A (zh)	2021-04-26	2023-02-01	美商千禧製藥公司	抗adgre2抗體及其用途
US20230111279A1 (en)	2021-04-26	2023-04-13	Millennium Pharmaceuticals, Inc.	Anti-clec12a antibodies and uses thereof
CA3236038A1 (fr)	2021-10-20	2023-04-27	Takeda Pharmaceutical Company Limited	Compositions ciblant bcma et leurs procedes d'utilisation
WO2023117967A1 (fr)	2021-12-21	2023-06-29	Chiesi Farmaceutici S.P.A.	Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
CN118475343A (zh)	2021-12-21	2024-08-09	凯西制药公司	填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023150747A1 (fr)	2022-02-07	2023-08-10	Insmed Incorporated	Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation
WO2024062007A1 (fr)	2022-09-22	2024-03-28	Chiesi Farmaceutici S.P.A.	Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
GB1381872A (en)	1971-06-22	1975-01-29	Fisons Ltd	Pharmaceutical compositions for inhalation
GB1520247A (en)	1974-08-10	1978-08-02	Fisons Ltd	Pelletised medicament formulations
GB1571629A (en)	1977-11-30	1980-07-16	Fisons Ltd	Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) *	1979-06-08	1982-09-14	National Research Development Corporation	Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
EP0441740B1 (fr)	1990-01-29	1993-09-22	Ciba-Geigy Ag	Procédé et dispositif pour le dosage d'une poudre à grains fins
DE4140689B4 (de) *	1991-12-10	2007-11-22	Boehringer Ingelheim Kg	Inhalationspulver und Verfahren zu ihrer Herstellung
US5626871A (en)	1992-06-12	1997-05-06	Teijin Limited	Preparation for intratracheobronchial administration
GB2269992A (en)	1992-08-14	1994-03-02	Rh Ne Poulenc Rorer Limited	Powder inhalation formulations
GB9322014D0 (en) *	1993-10-26	1993-12-15	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en)	1994-03-15	1994-04-27	Glaxo Group Ltd	Pharmaceutical composition
DE4425255A1 (de)	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
SE9700136D0 (sv)	1997-01-20	1997-01-20	Astra Ab	New formulation
SE9700134D0 (sv)	1997-01-20	1997-01-20	Astra Ab	New formulation
GB9501841D0 (en) *	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) *	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
AR015173A1 (es) *	1997-09-30	2001-04-18	Mortimer Tech Holdings	Un procedimiento para el tratamiento de material particulado, en el cual particulas del material a ser tratado interactuan con particulas no estaticas deun segundo material, una mena calcinada que se obtiene mediante dicho procedimiento, un reactor para exponer particulas huesped a un fluido y un re
SK13632000A3 (sk) *	1998-03-16	2001-03-12	Inhale Therapeutic Systems, Inc.	Spôsob podávania aktívnej látky do pľúc ľudského pacienta a zariadenie na jeho vykonávanie
DK1131059T3 (da)	1998-11-13	2003-06-30	Jago Res Ag	Tørpulver til inhalation
GB9826783D0 (en)	1998-12-04	1999-01-27	Scherer Ltd R P	Inhalation powders
DE69936268T2 (de)	1999-03-05	2008-02-14	Chiesi Farmaceutici S.P.A.	Verbesserte pulverförmige pharmazeutische Zusammensetzungen zur Verwendung in Trockenpulverinhalatoren
DE60044070D1 (de) *	1999-10-29	2010-05-06	Novartis Ag	Trockenpulverzusammensetzungen mit verbesserter Dispersität
PE20011227A1 (es) *	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) *	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) *	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formulations for use in inhaler devices
DK1913939T3 (en) *	2000-06-27	2017-09-18	Vectura Ltd	Formulations for use in inhalers

2001
- 2001-04-11 PE PE2001000338A patent/PE20011227A1/es active IP Right Grant
- 2001-04-16 TN TNTNSN01060A patent/TNSN01060A1/fr unknown
- 2001-04-17 ES ES01931612T patent/ES2272473T3/es not_active Expired - Lifetime
- 2001-04-17 SI SI200130658T patent/SI1274406T1/sl unknown
- 2001-04-17 EP EP10185445.3A patent/EP2272508B1/fr not_active Expired - Lifetime
- 2001-04-17 DE DE60125344T patent/DE60125344T2/de not_active Expired - Lifetime
- 2001-04-17 EP EP06017742A patent/EP1719505B1/fr not_active Expired - Lifetime
- 2001-04-17 EP EP01931612A patent/EP1274406B1/fr not_active Expired - Lifetime
- 2001-04-17 DK DK06017742.5T patent/DK1719505T3/da active
- 2001-04-17 KR KR1020027013929A patent/KR20030069047A/ko not_active Application Discontinuation
- 2001-04-17 WO PCT/EP2001/004338 patent/WO2001078693A2/fr active IP Right Grant
- 2001-04-17 ES ES01921610T patent/ES2275669T3/es not_active Expired - Lifetime
- 2001-04-17 US US10/257,368 patent/US6884794B2/en not_active Expired - Lifetime
- 2001-04-17 EP EP07110708A patent/EP1829533B1/fr not_active Revoked
- 2001-04-17 BR BR0110139-0A patent/BR0110139A/pt not_active Application Discontinuation
- 2001-04-17 EP EP01921625A patent/EP1276473B1/fr not_active Revoked
- 2001-04-17 AT AT01921625T patent/ATE377416T1/de not_active IP Right Cessation
- 2001-04-17 CZ CZ20023437A patent/CZ301904B6/cs not_active IP Right Cessation
- 2001-04-17 PT PT01921610T patent/PT1276472E/pt unknown
- 2001-04-17 HU HU1300117A patent/HU230464B1/hu unknown
- 2001-04-17 AU AU2001258343A patent/AU2001258343A1/en not_active Abandoned
- 2001-04-17 WO PCT/GB2001/001751 patent/WO2001078695A2/fr active IP Right Grant
- 2001-04-17 CN CN01808256A patent/CN1424909A/zh active Pending
- 2001-04-17 IL IL15230601A patent/IL152306A0/xx unknown
- 2001-04-17 AT AT06017742T patent/ATE521340T1/de active
- 2001-04-17 US US10/257,790 patent/US8182791B2/en not_active Expired - Fee Related
- 2001-04-17 AT AT01931612T patent/ATE339195T1/de active
- 2001-04-17 SA SA01220062A patent/SA01220062B1/ar unknown
- 2001-04-17 HU HU0300499A patent/HU229270B1/hu unknown
- 2001-04-17 EP EP01921610A patent/EP1276472B1/fr not_active Revoked
- 2001-04-17 DE DE60123031T patent/DE60123031T2/de not_active Expired - Lifetime
- 2001-04-17 JP JP2001575995A patent/JP2003530425A/ja active Pending
- 2001-04-17 DK DK01921610T patent/DK1276472T3/da active
- 2001-04-17 WO PCT/GB2001/001732 patent/WO2001078694A2/fr active IP Right Grant
- 2001-04-17 AT AT01921610T patent/ATE348603T1/de active
- 2001-04-17 AU AU48581/01A patent/AU784719B2/en not_active Ceased
- 2001-04-17 MX MXPA02010213A patent/MXPA02010213A/es active IP Right Grant
- 2001-04-17 EE EEP200200593A patent/EE05257B1/xx unknown
- 2001-04-17 BR BR0110141-2A patent/BR0110141A/pt not_active Application Discontinuation
- 2001-04-17 PT PT06017742T patent/PT1719505E/pt unknown
- 2001-04-17 MX MXPA02010212A patent/MXPA02010212A/es active IP Right Grant
- 2001-04-17 PL PL358875A patent/PL204213B1/pl unknown
- 2001-04-17 GB GB0109431A patent/GB2363987A/en not_active Withdrawn
- 2001-04-17 ES ES01921625T patent/ES2292576T3/es not_active Expired - Lifetime
- 2001-04-17 MX MXPA02010218A patent/MXPA02010218A/es active IP Right Grant
- 2001-04-17 CA CA002406119A patent/CA2406119C/fr not_active Expired - Lifetime
- 2001-04-17 CA CA2406201A patent/CA2406201C/fr not_active Expired - Fee Related
- 2001-04-17 SI SI200131003T patent/SI1719505T1/sl unknown
- 2001-04-17 NZ NZ521887A patent/NZ521887A/en unknown
- 2001-04-17 SK SK1491-2002A patent/SK284248B6/sk not_active IP Right Cessation
- 2001-04-17 GB GB0109432A patent/GB2363988A/en not_active Withdrawn
- 2001-04-17 HU HU0300490A patent/HUP0300490A2/hu unknown
- 2001-04-17 CA CA2405767A patent/CA2405767C/fr not_active Expired - Lifetime
- 2001-04-17 AT AT07110708T patent/ATE513542T1/de active
- 2001-04-17 AU AU48595/01A patent/AU4859501A/en not_active Abandoned
- 2001-04-17 HU HU0300593A patent/HU229797B1/hu unknown
- 2001-04-17 DK DK01931612T patent/DK1274406T3/da active
- 2001-04-17 PL PL01358640A patent/PL358640A1/xx not_active Application Discontinuation
- 2001-04-17 DE DE60131265T patent/DE60131265T2/de not_active Revoked
- 2001-04-17 DZ DZ013315A patent/DZ3315A1/fr active
- 2001-04-17 PT PT01931612T patent/PT1274406E/pt unknown
- 2001-04-17 PL PL359289A patent/PL204251B1/pl unknown
- 2001-04-17 MY MYPI20011834A patent/MY129384A/en unknown
- 2001-04-17 BR BR0110301-6A patent/BR0110301A/pt not_active Application Discontinuation
2002
- 2002-10-04 MA MA26851A patent/MA26892A1/fr unknown
- 2002-10-16 NO NO20024973A patent/NO342999B1/no not_active IP Right Cessation
- 2002-10-16 NO NO20024980A patent/NO332025B1/no not_active IP Right Cessation
- 2002-10-16 NO NO20024971A patent/NO20024971L/no not_active Application Discontinuation
2005
- 2005-03-08 US US11/073,625 patent/US7223748B2/en not_active Expired - Lifetime
2006
- 2006-11-28 CY CY20061101708T patent/CY1107315T1/el unknown
2011
- 2011-06-20 NO NO20110885A patent/NO336687B1/no not_active IP Right Cessation
2012
- 2012-04-25 US US13/455,277 patent/US20120308613A1/en not_active Abandoned
- 2012-09-28 JP JP2012217416A patent/JP2012255035A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US20050201950A1 (en)	2005-09-15
CA2406119A1 (fr)	2001-10-25
SI1274406T1 (sl)	2007-02-28
EE05257B1 (et)	2010-02-15
CY1107315T1 (el)	2012-11-21
MY129384A (en)	2007-03-30
AU784719B2 (en)	2006-06-01
NO336687B1 (no)	2015-10-19
EP2272508B1 (fr)	2020-03-25
DE60123031T2 (de)	2007-03-08
KR20030069047A (ko)	2003-08-25
WO2001078695A3 (fr)	2002-03-14
CZ20023437A3 (cs)	2003-02-12
EP2272508A3 (fr)	2012-01-18
NO20024973D0 (no)	2002-10-16
EP1276473A2 (fr)	2003-01-22
CA2406201A1 (fr)	2001-10-25
DE60131265T2 (de)	2008-03-06
GB0109431D0 (en)	2001-06-06
ATE339195T1 (de)	2006-10-15
DZ3315A1 (fr)	2001-10-25
CA2406119C (fr)	2009-07-07
EP1719505A2 (fr)	2006-11-08
JP2003530425A (ja)	2003-10-14
NO342999B1 (no)	2018-09-24
NZ521887A (en)	2004-06-25
EP1829533A3 (fr)	2007-10-31
AU4859501A (en)	2001-10-30
NO20024980L (no)	2002-12-17
CA2406201C (fr)	2011-03-22
MXPA02010218A (es)	2003-05-23
PL358875A1 (en)	2004-08-23
PL358640A1 (en)	2004-08-09
DE60131265D1 (de)	2007-12-20
GB0109432D0 (en)	2001-06-06
PT1276472E (pt)	2007-02-28
US6884794B2 (en)	2005-04-26
DK1274406T3 (da)	2007-01-22
SK14912002A3 (sk)	2003-03-04
NO20024980D0 (no)	2002-10-16
DE60123031D1 (de)	2006-10-26
EP1719505B1 (fr)	2011-08-24
BR0110139A (pt)	2002-12-31
TNSN01060A1 (fr)	2005-11-10
MXPA02010212A (es)	2004-06-29
BR0110141A (pt)	2003-01-28
HUP0300593A3 (en)	2006-07-28
EE200200593A (et)	2004-04-15
PT1274406E (pt)	2007-01-31
PE20011227A1 (es)	2002-01-07
ATE348603T1 (de)	2007-01-15
ATE521340T1 (de)	2011-09-15
WO2001078694A2 (fr)	2001-10-25
EP1829533B1 (fr)	2011-06-22
NO20024971D0 (no)	2002-10-16
US7223748B2 (en)	2007-05-29
NO332025B1 (no)	2012-05-29
DK1276472T3 (da)	2007-04-16
PL359289A1 (en)	2004-08-23
PT1719505E (pt)	2011-10-24
SK284248B6 (sk)	2004-12-01
GB2363987A (en)	2002-01-16
EP1276473B1 (fr)	2007-11-07
HUP1300117A2 (en)	2003-07-28
US20030180227A1 (en)	2003-09-25
JP2012255035A (ja)	2012-12-27
NO20110885L (no)	2002-12-17
DE60125344T2 (de)	2007-07-19
DE60125344D1 (de)	2007-02-01
IL152306A0 (en)	2003-05-29
SA01220062B1 (ar)	2006-11-05
GB2363988A (en)	2002-01-16
CA2405767A1 (fr)	2001-10-25
CN1424909A (zh)	2003-06-18
EP1719505A3 (fr)	2007-07-18
NO20024973L (no)	2002-12-16
HUP0300593A2 (hu)	2003-09-29
BR0110301A (pt)	2003-12-30
AU4858101A (en)	2001-10-30
EP1276472A2 (fr)	2003-01-22
US20120308613A1 (en)	2012-12-06
PL204213B1 (pl)	2009-12-31
WO2001078694A3 (fr)	2002-03-14
EP1274406B1 (fr)	2006-09-13
MXPA02010213A (es)	2005-07-01
SI1719505T1 (sl)	2011-12-30
WO2001078693A3 (fr)	2002-01-17
ES2275669T3 (es)	2007-06-16
ATE513542T1 (de)	2011-07-15
WO2001078695A2 (fr)	2001-10-25
HU230464B1 (hu)	2016-07-28
CZ301904B6 (cs)	2010-07-28
HU229797B1 (en)	2014-07-28
AU2001258343A1 (en)	2001-10-30
DK1719505T3 (da)	2011-12-05
EP1276472B1 (fr)	2006-12-20
US8182791B2 (en)	2012-05-22
US20030175214A1 (en)	2003-09-18
EP1829533A2 (fr)	2007-09-05
EP1274406A2 (fr)	2003-01-15
PL204251B1 (pl)	2009-12-31
ATE377416T1 (de)	2007-11-15
EP2272508A2 (fr)	2011-01-12
HUP0300499A2 (en)	2003-07-28
ES2272473T3 (es)	2007-05-01
HU229270B1 (en)	2013-10-28
MA26892A1 (fr)	2004-12-20
CA2405767C (fr)	2011-07-05
ES2292576T3 (es)	2008-03-16
HUP0300490A2 (en)	2003-07-28
WO2001078693A2 (fr)	2001-10-25

Publication	Publication Date	Title
NO20024971L (no)	2002-12-17	Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger
EA200400045A1 (ru)	2004-06-24	Система для ингаляции сухим порошком для транспульмонарного применения
IT1303788B1 (it)	2001-02-23	Formulazioni di aerosol medicinali.
GB2453272A (en)	2009-04-01	Lumen-traveling device
DK1131059T3 (da)	2003-06-30	Tørpulver til inhalation
PE20020968A1 (es)	2002-12-10	Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
ATE364381T1 (de)	2007-07-15	Formulierungen zur verwendung in inhalationsvorrichtungen
MXPA02012023A (es)	2004-08-19	Administracion altamente eficiente de un aerosol de masa terapeutica grande.
DE50313403D1 (de)	2011-02-17	Pulverinhalator
MY127145A (en)	2006-11-30	Stable pharmaceutical solution formulations for pressurised metered dose inhalers
GEP20064002B (en)	2006-12-25	Metered dose inhaler
JO2430B1 (en)	2008-04-17	Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
RS49803B (sr)	2008-06-05	Primena lekovitih preparata rastvorenih u vodi za dobijanje aerosolova bez potisnog gasa
NZ334149A (en)	2000-07-28	Pharmaceutical aerosol composition containing an active material, a propellant containing a hydrofluoroalkane and a cosolvent and a low volatility component
DE60036534D1 (de)	2007-11-08	Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung
ATE219932T1 (de)	2002-07-15	Neue feste dosisform enthaltend nanopartikelnaproxen
BR9915095A (pt)	2002-01-15	Composição farmacêutica ministrável em aerosol
CY1110136T1 (el)	2015-01-14	Συνθεσεις ξηρης σκονης με βελτιωμενη διασπαρσιμοτητα
CO5280133A1 (es)	2003-05-30	Dispositivo y sistema para aerosolizar formulaciones farmaceuticas
AU2002316820A1 (en)	2002-10-21	Powder inhaler formulations
DE60108154D1 (de)	2005-02-03	Pharmazeutische Zubereitungen enthaltend Clavulansäure
PL318789A1 (en)	1997-07-07	Sprayable film-forming system capable to release an active substance contained in them and intended to use them on plants
NZ513981A (en)	2004-02-27	Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
GB2429652A (en)	2007-03-07	Animal bit
GEP20074268B (en)	2007-12-25	Dry powder inhalation system for transpulmonary administration

Legal Events

Date	Code	Title	Description
2008-11-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application